3rd ESTRO Forum 2015 classes of CBV TUMOR were reported to the total CBV TUMOR to show volume variations in percentage. Results: Variations of median rCBV between M0 and M2 were different for two groups of patients: rCBV increased when initial rCBV was <1.0 (Group_rCBV_M0<1) and rCBV decreased when initial rCBV was >=1.0 (Group_rCBV_M0>1), this was statistically significant (p<0.013). Mapping of color-coded voxels between M0 and M2 provided additional spatial and quantitative information about tumor perfusion: Group_rCBV_M0>1 presented a significant decrease of High_CBV TUMOR volume (p=0.015) simultaneously with a significant increase of the Normal_CBV TUMOR volume (p=0.012) after treatment. Group_rCBV_M0<1 presented a significant decrease of Low_CBV TUMOR volume (p=0.035) after treatment and an increase of the Normal_ and High_CBV TUMOR volumes. Two examples of these CBV TUMOR volumes variations between M0 and M2 are illustrated for a patient of each group over their anatomical MRI, respectively Fig1A for a patient of Group_rCBV_M0>1 and Fig1B for a patient of Group_rCBV_M0<1.
classes of CBV TUMOR were reported to the total CBV TUMOR to show volume variations in percentage. Results: Variations of median rCBV between M0 and M2 were different for two groups of patients: rCBV increased when initial rCBV was <1.0 (Group_rCBV_M0<1) and rCBV decreased when initial rCBV was >=1.0 (Group_rCBV_M0>1), this was statistically significant (p<0.013). Mapping of color-coded voxels between M0 and M2 provided additional spatial and quantitative information about tumor perfusion: Group_rCBV_M0>1 presented a significant decrease of High_CBV TUMOR volume (p=0.015) simultaneously with a significant increase of the Normal_CBV TUMOR volume (p=0.012) after treatment. Group_rCBV_M0<1 presented a significant decrease of Low_CBV TUMOR volume (p=0.035) after treatment and an increase of the Normal_ and High_CBV TUMOR Purpose/Objective: Lung cancer is the leading cause of cancer death worldwide and alternative treatment strategies are needed to eradicate non-responsive or recurrent tumor cells. The Notch signaling pathway plays a key role during normal lung development and is frequently deregulated in non small cell lung cancer (NSCLC) making it a potentially attractive therapeutic target. We and others have shown that in NSCLC xenografts high Notch activity is correlated with faster proliferation, higher hypoxic fraction and resistance to radiotherapy. These findings have led us to further investigate the interactions between standard of care treatments (chemo/radiotherapy) in conjunction with Notch inhibitors both in vitro and in vivo. Materials and Methods: Monolayer cultures of diverse lung cell lines were used to determine the IC50 value by measuring the metabolic activity of the acid phosphotase enzyme in cells after treatment with a range of chemotherapeutic agents both as a monotherapy and in combination with Notch receptor inhibition. In addition, the effect of single and combined treatment schedules was tested using a quantitative spheroid growth delay assay. In vivo evaluation of therapeutic efficacy of the combination treatment before mentioned has been initiated using a xenograft lung cancer model. Results: IC50 value analysis of various chemotherapeutic agents revealed striking differences in responses across cell lines. The human lung cancer cell line H460 was more sensitive to etoposide, docetaxel and paclitaxel than different mouse cell lines deriving from mouse tumors bearing KRas and p53 mutations with different metastasizing potentialities (344P; 344SQ and 393P) but equally sensitive to cisplatin than 344P and 344SQ cell lines. The 393P cell line derived from a primary tumor that didn't metastasize was more resistant than the rest of the cell lines to cisplatin and paclitaxel. Interestingly, although Notch inhibition alone had no effect upon cell growth after 72h of treatment, the combination with either cisplatin or etoposide resulted in a growth delay with respect to the monotherapy treatment. In spheroid cultures of H460 cells the combination of 2.5uM cisplatin with 4 uM DAPT (Notch inhibitor) instigated more growth delay than the monotherapy treatments. Experiments to quantify the growth delay when also radiation is given are underway. In addition, in vivo experiments are ongoing to investigate whether the synergistic drug combination found in vitro also applies for an in vivo model. Two different doses of cisplatin were tested in vivo whereby 3.5mg/kg had a good efficacy and better tolerance than 7mg/kg and therefore will be used to test the combination treatment with the dose of Notch inhibitor that yields an optimal response as monotherapy and with radiation. Conclusions: The addition of Notch inhibitors to cisplatin (chemotherapeutic used to treat lung cancer patients) leads to an enhanced treatment response in vitro and may lead to one in vivo as well.
Purpose/Objective: Novel targeted agents, such as PARP inhibitors, are combined with radiotherapy (RT) to induce tumor-specific radiosensitization. Safety and tolerability of olaparib in combination with RT is currently tested in several clinical phase 1 trials. When used as single agent in clinic, olaparib is well tolerated and has proven anti-tumor efficacy in BRCA1 and 2 mutation carriers. As the mechanisms of action of olaparib as radiosensitizer or as single agent may differ, also the dose range of tolerability and effectiveness might differ. In this in vitro study, we compared efficacy of 3rd ESTRO Forum 2015 S299 olaparib as radiosensitizer to efficacy of olaparib as single agent in cell systems with different genetic backgrounds. Materials and Methods: Mouse mammary tumor cell line with BRCA2 deficiency, its isogenic control cell line with restored BRCA2 function and a panel of human head and neck squamous cell carcinoma (HNSCC) cell lines were treated with different doses of olaparib and radiation. Survival was quantified using proliferation and clonogenic assays. To assess the effect of olaparib and radiation on PARP activity, we measured PAR levels using an ELISA-based immunoassay. Results: As reported previously, olaparib alone has efficacy at significantly lower concentrations in BRCA2-deficient cells than in BRCA2-proficient cells. Efficacy of olaparib alone differed among the human HNSCC cells. Olaparib radiosensitized all tested cell lines, however, to a different extent and at different dose ranges. Importantly, in all but one HNSCC cell line that is hypersensitive to olaparib alone, effective radiosensitization always established at tenfold lower concentrations than single agent activity. Radiation increased PAR levels in both BRCA2-deficient and BRCA2-proficient cells. Olaparib reduced PAR levels in a dose-dependent fashion and to a similar extent in BRCA2deficient and BRCA2-proficient cells. Low doses of olaparib that result in effective radiosensitization without concomitant single agent activity fully abolished PAR induction by radiation, without fully abolishing baseline PAR levels.
Conclusions:
Our results show that olaparib acts as an effective radiosensitizer at significantly lower doses than those required for single agent activity. We conclude that olaparib-induced radiosensitization occurs by the prevention of PAR induction upon radiation, rather than by full PARP inhibition as proposed to be required for single agent activity. From these data we would predict that radiosensitization may be present at low olaparib dose levels in the clinic. This study emphasizes the importance to evaluate the concept of biological optimal dosing in novel radiation-targeted agent combinations.
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Evaluation of the therapeutic optimality in radiotherapy for breast cancer with targeted gold nano-particles F. Veronica 1 , G. Visonà 1 , P. Cerello 2 , L. Strigari 3 , A. Purpose/Objective: In recent years there has been considerable interest on the use of gold nanoparticles (GNPs) combined with radiotherapy to improve tumor control. Radiosensitization in cancerous cells in presence of GNP has been demonstrated both in vitro and in vivo at kilo-and mega-voltage energies [1, 2, 3, 4] . GNPs exhibit unique physical and chemical properties, and can be designed to interact with various biomolecules, resulting in improved diagnosis and treatments efficacy when bound to molecules that target specific cell receptors. A quantification of the expected clinical improvements is however still lacking. In this work a new approach for estimating the improved nanoparticle-driven radiosensitivity is presented and a quantification of the treatment optimality as a function of GNP uptake is performed. Materials and Methods: In order to assess the biological effects, a stochastic radiobiological model derived from the Local Effect Model (LEM) [5, 6] approach was coupled with Monte Carlo simulations performed using Geant4 toolkit, so as to estimate the local dose deposited from secondary electrons at the nanometric level. A closed analytical formulation of the model was also derived for MV irradiation. The model was benchmarked for MDA-MB-231 breast cancer cells with varying gold concentration and then used to investigate breast cancer cases for planned treatments with both 6 MV and 15 MV photons. Treatment simulations of 6 patients were performed for each energy, in which a parametrization of the GNPs uptake with varying tumor selectivity was introduced. The expected treatment optimality as a function of the spatially varying gold uptake was quantified in terms of Tumor Control Probability (TCP) and Normal Tissue Complication Probability (NTCP). Results: Results show good agreement between simulations and experimental clonogenic survival assays for both 6 MV and 15 MV, suggesting that the models could be used to estimate the experimental outcomes in a clinical setup. The breast cancer treatment simulations show improved tumor control when GNPs bound to targeting agents are present. For both treatments with 3 Gy per fraction and 13 fractions (START A) and 2.67 Gy with 15 fractions (START B) [8], a maximum TCP increase of 20% was observed in the 6 MV case, assuming a maximum concentration of 12 uM GNP in the tumoral region. Conclusions: A model to account GNP uptake and tissue radiosentitization was implemented and included in the simulation of breast cancer treatments. In addition to the improved treatment efficacy, the possibility of a short course of fractionation in combination with GNP was also quantified. Purpose/Objective: A common characteristic of glioblastoma multiforme is radioresistance. Hence, novel treatment concepts involve the application of molecularly targeted agents that interfere with pathways mediating glioma cell radioresistance and invasiveness. One molecule contributing to glioblastoma cell growth and survival is the heat shock protein 90 (HSP90), a chaperone that regulates the proper folding and stability of numerous client proteins which are involved in promoting tumorigenesis, proliferation, invasion, and survival. The novel pochoxime-based HSP90 inhibitor NW457 binds to the N-terminal ATP binding site of HSP90, thus leading to the destabilization and proteasomal degradation of crucial client proteins. Here, we report on the mechanisms involved in NW457-mediated radiosensitization of human glioblastoma cell lines as well as on the impact of NW457 on the migratory phenotype. Materials and Methods: DNA damage response regulators were analyzed by qPCR. Treatment response of LN229 and T98G to ionizing radiation in the presence or absence of
